• A Global Leading
    Company In
    Antibody
    Therapeutics
  • Exploring Antibodies,

    Discovering Novel
    Therapeutics
  • Redesigning
    The MOA of
    Antibody
    Therapeutics

Founded in 2007, Y-Biologics is a renowned
biotech company
in South Korea for its expertise in
antibody science.
Since its foundation, we have dedicated ourselves to the discovery & development of novel antibody therapeutics.
By utilizing our two platform technologies Y-max ABLTM & ALiCETM in R&D process, we aim to be a leading
biopharmaceutical company in fields of immuno-oncology.

Proprietary BsAB Platform Technology
ALiCE (Antibody Like Cell Engager)
Safety
Minimizing toxicity through unique 2by1 structure
Easy to Make
Utilizing innate assembly mechanism of the cell lines to generate bispecific antibodies
Immunogenicity
A bispecific antibody without mutated domains
Antibody pipeline in various modalities
Bi-specific Antibody, Antibody-Drug Conjugate, Antibody
Since its foundation in 2007 Y-Biologics has dedicated itself to establish expertise in antibody science. Now we have secured strong candidates, discovered from our own antibody library.

VIEW MORE